Table 1.
Sociodemographic and clinical characteristics of the study population (N = 509), overall and according to the SARS-CoV-2 variant of concern (VOC).
| Parental (N = 387) | Delta (N = 52) | Omicron (N = 70) | Total (N = 509) | |
|---|---|---|---|---|
| Age in years, median (P25–P75) | 8.3 (4.37–11.87) | 7.18 (4.84–10.11) | 7.32 (4.09–9.8) | 8.08 (4.38–11.53) |
| 0–2 years | 67 (17.31) | 8 (15.38) | 10 (14.29) | 85 (16.70) |
| 3–4 years | 47 (12.14) | 7 (13.46) | 10 (14.29) | 64 (12.57) |
| 5–11 years | 165 (42.64) | 29 (55.77) | 37 (52.86) | 231 (45.38) |
| 12–20 years | 108 (27.91) | 8 (15.38) | 13 (18.57) | 129 (25.34) |
| Gender, N (%) | ||||
| Female | 178 (45.99) | 23 (44.23) | 33 (47.14) | 234 (45.97) |
| Male | 209 (54.01) | 29 (55.77) | 37 (52.86) | 275 (54.03) |
| Number of symptoms, N (%) | ||||
| 0 | 124 (32.04) | 13 (25) | 2 (2.86) | 139 (27.31) |
| 1 | 110 (28.42) | 10 (19.23) | 14 (20) | 134 (26.33) |
| 2 | 69 (17.83) | 14 (26.92) | 21 (30) | 104 (20.43) |
| ≥3 | 84 (21.71) | 15 (28.85) | 33 (47.14) | 132 (25.93) |
| Vaccinations statusb, N (%) | ||||
| Without primary vaccinations | 54 (14.36) | 6 (11.76) | 17 (24.64) | 77 (15.52) |
| Primary vaccinations | 322 (85.64) | 45 (88.24) | 52 (75.36) | 419 (84.48) |
| Rotavirus vaccinesa, N (%) | ||||
| No | 119 (31.32) | 10 (19.61) | 19 (27.14) | 148 (29.54) |
| Yes | 261 (68.68) | 41 (80.39) | 51 (72.86) | 353 (70.46) |
| Flu vaccines 19–21c, N (%) | ||||
| No | 286 (85.12) | 22 (88) | 19 (76) | 327 (84.72) |
| Yes | 50 (14.88) | 3 (12) | 6 (24) | 59 (15.28) |
| COVID vaccinationd, N (%) | ||||
| First Dose | 4 (1.78) | 2 (5.26) | 24 (48) | 30 (9.58) |
| Second Dose | 0 (0) | 0 (0) | 1 (100) | 1 (100) |
| Comorbiditiese, N (%) | ||||
| 0 | 303 (78.29) | 41 (78.85) | 46 (65.71) | 390 (76.62) |
| At least 1 | 84 (21.71) | 11 (21.15) | 24 (34.29) | 119 (23.38) |
Patients aged at least 61 days.
Patients aged at least 3 months, 13 missing values are handled in the analysis.
Patients aged at least 6 months, 94 missing values are handled in the analysis.
Patients aged at least 5 years, 50 & 362 missing values are handled in the analysis respectively for first and second dose.
Among 509 individuals, prematurity (N = 8), obesity (N = 2), diabetes mellitus (N = 2), asthma (N = 11), congenital heart disease (N = 4), rheumatic conditions (N = 3), nephropathy (N = 3), neurologic disorders (N = 4), chronic hepatitis (N = 3), other comorbidities (N = 92). “Other comorbidities” included conditions that were not classified as risk factors for severe COVID-19 (15, 16), such as respiratory and food allergies, atopic dermatitis, recurrent urinary tract infections, hearing loss, irritable bowel syndrome and inflammatory bowel diseases, celiac disease, dermatological diseases, febrile seizure, behavior alterations, and periodic fever.